The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Examining the Use of CDK4/6 Inhibitors in HER2-Negative Breast Cancer

Debu Tripathy, MD
Published Online:6:09 PM, Thu February 21, 2019


Debu Tripathy, MD, professor and chair, Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses the use of CDK4/6 inhibitors for the treatment of HER2-negative breast cancer, based on results from the phase III MONALEESA-7 trial.

Tripathy says physicians are more likely to use CDK4/6 inhibitors now, especially in patients with visceral disease who may be symptomatic. Previously, the concern was that endocrine therapy was not enough and chemotherapy was necessary. Now, data is showing higher response rates.

There is still a lot of debate on whether patients should receive chemotherapy anyway, but Tripathy believes this allows the threshold to be set a bit differently and save more patients from getting chemotherapy.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.